Filed CTA review issues
All issues were filed in pirl-unc/oncoref on 25 October 2026. They originally tracked proposed decisions. The completed adjudications and current policy now document the implemented outcomes. Biological specificity follow-ups and broader literature coverage remain explicit.
| Issue | Work |
|---|---|
| #627 | Assign CTA / Neither / Unsafe from reviewed evidence with general, auditable rules |
| #628 | Adjudicate human neuronal FTMT protein and remove unrestricted CTA eligibility |
| #629 | Adjudicate normal neural ABCC11 protein before unrestricted CTA use |
| #630 | Resolve normal vascular and adrenal YBX2 protein against retained CTA status |
| #631 | Adjudicate renal CCDC158 protein and separate gene-level from isoform targeting |
| #632 | Curate normal keratinocyte ACTRT1 protein as non-reproductive evidence |
| #633 | Hold unrestricted MAGEC2 targeting while Purkinje-cell staining is unresolved |
| #634 | Resolve extra-placental PP13/LGALS13 protein and galectin specificity |
| #635 | Resolve pancreatic NYD-SP27/PLCZ1 evidence before unrestricted CTA use |
| #636 | Reconcile primary normal-antibody signals for 180 retained CTA assignments |
| #637 | Measure continuous normal-expression breadth without rescue by a reproductive maximum |
| #638 | Complete individual CTA literature adjudication beyond the 32-gene initial review |
The parent contains the full proposed rules. The individual gene issues contain exact identities, source-native measurements, primary citations, review limitations and acceptance criteria.
Related existing issues: #599 shared species facts, #620 active policy manifest, and #607 figure semantics.